Salvage radiotherapy in the treatment of prostate cancer

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 63-68

  Tsien, Christina ^a   Sandler, Howard ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CANCER VACCINE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR PROTEIN;

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; HORMONAL THERAPY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; RECTUM DISEASE; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BLOOD; CANCER INVASION; DISEASE FREE SURVIVAL; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RADIOTHERAPY; RISK FACTOR; STATISTICAL ANALYSIS; TUMOR RECURRENCE;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 1842840801     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.08.002     Document Type: Article

References (38)

1. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999.
2. Ornstein DK, Colberg JW, Virgo KS, et al: Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 52: 1047-1054, 1998.
3. Morris MM, Dallow KC, Zietman A, et al: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38: 731-736, 1997.
4. Petrovich Z, Lieskovsky G, Langholz B, et al: Radical prostatectomy and post-operative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Urology 53: 1184-1193, 1999.
5. Vicini F, Ziaja EL, Kestin LL, et al: Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 54: 111-117, 1999.
6. Pisansky TM, Kozelsky TF, Myers RP, et al: Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163: 845-850, 2000.
7. Anscher M, Clough R, Dodge R, et al: Radiotherapy for a rising PSA after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48: 369-375, 2000.
8. Cadeddu J, Partin A, DeWeese T, et al: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159: 173-177, 1998.
9. Tsien C, Griffith K, Sandler H, et al: Long-term results of 3D conformal radiotherapy following radical prostatectomy. Urology 62: 93-98, 2003.
10. Schild SE, Wong WW, Grado G, et al: The use of radiotherapy for patients with isolated increases of serum PSA levels following radical prostatectomy. Mayo Clin Proc 69: 613-619, 1994.
11. Parker C, Warde P, and Catton C: Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 61: 107-116, 2001.
12. Raj GV, Partin AW, and Polascik TJ: Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94: 987-996, 2002.
13. Chu LW, Troncoso P, Johnston DA, et al: Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 36: 303-312, 2003.
14. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565, 2001.
15. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517-523, 2003.
16. Kupelian P, Katcher J, Levin H, et al: Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48: 249-260, 1996.
17. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19: 1030-1039, 2001.
18. Anscher MS, and Prosnitz LR: Multivariate analysis of factors predicting local relapse after radical prostatectomy: possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 21: 941-947, 1991.
19. Nudell DM, Grossfeld GD, Weinberg VK, et al: Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 54: 1049-1057, 1999.
20. Epstein JI, Partin AW, Sauvageot J, et al: Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20: 286-292, 1996.
21. Han M, Pound CR, and Potter SR: Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol 165: 864-866, 2001.
22. Grossfeld GD, Chang JJ, Broering JM, et al: Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol 163: 1171-1177, 2000.
23. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158: 1441-1445, 1997.
24. Pollack A, Zagars GK, el-Naggar AK, et al: Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44: 711-718, 1994.
25. Cox JD, Gallagher MJ, Hammond EH, et al: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 17: 1155-1172, 1999.
26. Van der Kooy MJ, Pisansky TM, Cha SS, et al: Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 49: 65-70, 1997.
27. Eulau SM, Tate DJ, Stanley TA, et al: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41: 735-740, 1998.
28. Valicenti RK, Gomella LG, Ismail M, et al: Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology 52: 1034-1040, 1998.
29. Zelefsky M, Aschkenasy E, Kelsen S, et al: Tolerance and early outcome results of postprostatectomy 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 39: 327-333, 1997.
30. Katz MS, Zelefsky MJ, Venkatraman ES, et al: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21: 483-489, 2003.
31. Litwin MS, Lubeck DP, Henning JM, et al: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 159: 1988-1992, 1998.
32. Rogers R, Grossfeld GD, Roach M III, et al: Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol 160: 1748-1753, 1998.
33. Medini E, Medini I, Reddy PK, et al: Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy: a long term follow-up. Cancer 78: 1254-1259, 1996.
34. Do T, Parker RG, Do C, et al: Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4: 324-330, 1998.
35. Catton C, Gospodarowicz M, Warde P, et al: Adjuvant and salvage radiotherapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59: 51-60, 2001.
36. Peschel RE, Robnett TJ, Hesse D, et al: PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int J Cancer 90: 29-36, 2000.
37. McCarthy JF, Catalona WJ, Hudson MA, et al: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol 151: 1575-1578, 1994.
38. Thompson I, Crawford E, Miller G, et al: Adjuvant radiotherapy following radical prostatectomy for pathologic stage C adenocarcinoma of the prostate: initial evaluation of toxicity [abstract]. Proc Soc Clin Oncol 11: 212A, 1992.